White House Blocks FDA Rule Ensuring Vaccine Safety

The transcript discusses the safety measures for potential COVID-19 vaccines, highlighting the FDA's initial requirement for a two-month follow-up period to monitor side effects. However, a Trump administration official confirmed the reversal of this waiting period, stating it had no clinical value. This change was likely to ensure a vaccine could be released before Election Day, aligning with President Trump's promises.

What was the FDA's initial requirement for monitoring test subjects after receiving a COVID-19 vaccine?

• Six months

• Three months

• Two months

• One month

Why did the Trump administration reverse the FDA's two-month monitoring requirement?

• It was too costly

• It was not scientifically proven

• It had no clinical or medical value

• It was too time-consuming

Who confirmed the reversal of the FDA's monitoring requirement?

• An FDA spokesperson

• A WHO representative

• A Trump administration official

• A CDC official

What was the potential consequence of the FDA's initial monitoring requirement on the vaccine release timeline?

• It would ensure a higher efficacy rate

• It would have no impact on the timeline

• It would speed up the release process

• It would delay the release until after Election Day

How did President Trump relate the vaccine release timeline to the upcoming Election Day?

• He promised a release after Election Day

• He promised a release on Election Day

• He promised a release before Election Day

• He did not mention Election Day